1. Academic Validation
  2. Antitumor Activity of Vanicoside B Isolated from Persicaria dissitiflora by Targeting CDK8 in Triple-Negative Breast Cancer Cells

Antitumor Activity of Vanicoside B Isolated from Persicaria dissitiflora by Targeting CDK8 in Triple-Negative Breast Cancer Cells

  • J Nat Prod. 2019 Nov 22;82(11):3140-3149. doi: 10.1021/acs.jnatprod.9b00720.
Donghwa Kim 1 Cai Yi Wang 1 Ruoci Hu 1 Ji Yun Lee 1 Thi-Thu-Trang Luu 1 Hee-Juhn Park 2 Sang Kook Lee 1
Affiliations

Affiliations

  • 1 College of Pharmacy, Natural Products Research Institute , Seoul National University , Seoul 08826 , Republic of Korea.
  • 2 Department of Pharmaceutical Engineering , Sangji University , Wonju 26339 , Republic of Korea.
Abstract

A flavonoid glycoside, quercitrin (1), and two phenylpropanoyl sucrose derivatives, vanicoside B (2) and lapathoside C (3), were isolated for the first time from the herb Persicaria dissitiflora. Vanicoside B (2) exhibited antiproliferative activity against a panel of Cancer cell lines in triple-negative breast Cancer (TNBC) MDA-MB-231 cells. The underlying mechanisms of the antitumor activity of 2 were investigated in TNBC cells. Upregulation of cyclin-dependent kinase 8 (CDK8) was observed in a claudin-low molecular subtype of TNBC cells. A molecular modeling study indicated that 2 showed a high affinity for CDK8. Further investigations revealed that 2 suppressed CDK8-mediated signaling pathways and the expression of epithelial-mesenchymal transition proteins and induced cell cycle arrest and Apoptosis in MDA-MB-231 and HCC38 TNBC cells. Moreover, 2 inhibited tumor growth without overt toxicity in a nude mouse xenograft model implanted with MDA-MB-231 cells. Taken together, these findings demonstrate the significance of CDK8 activity in TNBC and suggest a potential use of 2 as a therapeutic candidate for the treatment of aggressive human triple-negative breast Cancer.

Figures
Products